GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Parmax Pharma Ltd

Parmax Pharma Board Meeting to Approve Q2 FY27 Results and Registered Office Shift

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 10 Nov 2026, 07:44 PM IST  ·  BSE ID: b4fb2318-f3c3-42fe-9e64-853b583e22df
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board will meet on November 13, 2026, to approve its Q2 FY27 earnings and discuss moving its office.
🤖 AI Summary
  • Parmax Pharma Board of Directors meeting scheduled for November 13, 2026.
  • Meeting to consider and approve unaudited financial results for Q2 FY27 and half year ended September 30, 2026.
  • Board agenda also includes discussion on shifting the Registered Office of the Company.
  • Trading window for company securities closed until 48 hours post-financial results announcement.
🏢 How This Affects the Company
⚙️
Operational Impact
The Board's discussion on shifting the Registered Office indicates a potential change in the company's administrative location and operational setup.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this intimation of a Board Meeting.
👤
Who Is Affected
All shareholders are affected as the company prepares to release its Q2 FY27 financial performance, which will provide an update on its operational and financial health.
🔍
Management Signal
The management is adhering to regulatory requirements by intimating the Board Meeting for financial results approval and considering operational changes like shifting the Registered Office.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Outcome of Board Meeting on November 13, 2026 — check for Q2 FY27 financial results.
Details of the financial results — assess net profit/loss and revenue figures.
Announcement regarding the shifting of the Registered Office — details on new location.
LOW RISK This filing is a procedural announcement of a board meeting; no specific risks are indicated within the document.
💡 Investor Takeaway
Parmax Pharma has scheduled a Board Meeting on November 13, 2026, to approve unaudited financial results for the quarter and half year ended September 30, 2026 (Q2 FY27). The agenda also includes a discussion on shifting the company's Registered Office.
📅 Company Track Record
Parmax Pharma reported a net loss of -5843.31 Rs. Thousands for Q4 FY26. For the full FY26, the company's net loss widened to -41590.82 Rs. Thousands, as reported in June 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is Parmax Pharma's Board of Directors meeting scheduled?
Parmax Pharma's Board of Directors meeting is scheduled for Friday, November 13, 2026.
What financial results will the Board consider at the meeting?
The Board will consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026 (Q2 FY27).
What other matters are on the Board Meeting agenda?
In addition to financial results, the Board will discuss the shifting of the Registered Office of the Company.
Is the trading window for Parmax Pharma securities currently open?
No, the trading window for dealing in Parmax Pharma securities has been closed until forty-eight hours after the announcement of the financial results for the quarter and half year ended September 30, 2026.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.